Amgen Inc ( (AMGN) ) has released its Q2 earnings. Here is a breakdown of the information Amgen Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc., a leading biotechnology company, specializes in developing innovative medicines for serious diseases, including cancer, heart disease, and rare conditions. In its recent earnings report for the second quarter of 2025, Amgen announced a 9% increase in total revenues, reaching $9.2 billion, with product sales also growing by 9%. The company’s GAAP earnings per share saw a significant rise of 92%, driven by increased revenues, while non-GAAP EPS rose by 21%. Key products such as Repatha and EVENITY showed strong double-digit sales growth, and the company continued to invest in its research and development programs, including the promising MariTide studies. Looking ahead, Amgen remains focused on sustainable, long-term growth, with a projected revenue range of $35.0 billion to $36.0 billion for the full year 2025, and continued investment in its robust pipeline of innovative treatments.